Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 12/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.53 |
| ▸ | AR | P10275 | 8/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497957 | 1.00 | PGR (0.53) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL5496193 | 0.90 | PGR (0.54) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL5499190 | 0.88 | PGR (0.56) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL5498124 | 0.85 | PGR (0.49) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL2122881 | 0.85 | AR (0.59) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL5499215 | 0.85 | PGR (0.54) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL7535722 | 0.85 | PGR (0.54) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL7535727 | 0.85 | PGR (0.54) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL5499212 | 0.85 | PGR (0.54) | PGRNR3C1ARCYP3A4LMNA | |
| SCHEMBL5499568 | 0.85 | PGR (0.54) | PGRNR3C1ARCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080060-A1 | Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-14 | — | — | US | claimed |
| US-6806263-B2 | NEW 17 ALPHA -FLUOROALKYL STEROIDS OF GENERAL FORMULA I AS ANTIESTROGENS | SCHERING AG (DE) | 2004-10-19 | — | — | US | claimed |
| US-20030134834-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | SCHERING AG (DE) | 2003-07-17 | — | — | US | claimed |
| US-6503895-B2 | Antigestagenically active steroids with a fluorinated 17α-alkyl chain | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | claimed |
| US-20020045774-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-18 | — | — | US | claimed |
| EP-0970103-B1 | ANTIGESTAGENIC STEROIDS WITH A FLUORINATED 17ALPHA-ALKYL CHAIN | SCHERING AG (DE) | 2002-04-17 | — | — | EP | claimed |
| US-6316432-B1 | ANTIESTROGENS AND ANTIFERTILITY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | claimed |
| EP-1365765-B1 | THE USE OF ANTIGESTAGENS FOR INHIBITING ACCELERATED ENDOMETRIAL MATURATION DURING INFERTILITY TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-7148213-B2 | Antigestagenically active steroids with a fluorinated 17α-alkyl chain | SCHERING AG (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050080060-A1 | Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-14 | — | — | US | disclosed |
| US-6806263-B2 | NEW 17 ALPHA -FLUOROALKYL STEROIDS OF GENERAL FORMULA I AS ANTIESTROGENS | SCHERING AG (DE) | 2004-10-19 | — | — | US | disclosed |
| US-20040152684-A1 | Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-08-05 | — | — | US | disclosed |
| US-20030134834-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | SCHERING AG (DE) | 2003-07-17 | — | — | US | disclosed |
| US-6503895-B2 | Antigestagenically active steroids with a fluorinated 17α-alkyl chain | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20020045774-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-18 | — | — | US | disclosed |
| EP-0970103-B1 | ANTIGESTAGENIC STEROIDS WITH A FLUORINATED 17ALPHA-ALKYL CHAIN | SCHERING AG (DE) | 2002-04-17 | — | — | EP | disclosed |
| US-6316432-B1 | ANTIESTROGENS AND ANTIFERTILITY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134834-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | HSD17B11, HSD3B1, CYP17A1 | PGR 71/4885NR3C1 52/4885AR 149/4885 |
| US-20040152684-A1 | Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment | FSHR, GNRHR, NR5A1 | PGR 4/4885NR3C1 61/4885AR 118/4885 |
| US-20020045774-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | HSD17B11, NR5A1, HSD3B1 | PGR 52/4885NR3C1 31/4885AR 186/4885 |
| US-20050080060-A1 | Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain | NR5A1, HSD17B11, CYP21A2 | PGR 40/4885NR3C1 17/4885AR 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.